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Background. The mammalian CLC protein family comprises nine members (ClC-1 to -7 and ClC-Ka, -Kb) that function either as
plasma membrane chloride channels or as intracellular chloride/proton antiporters, and that sustain a broad spectrum of
cellular processes, such as membrane excitability, transepithelial transport, endocytosis and lysosomal degradation. In this
study we focus on human ClC-6, which is structurally most related to the late endosomal/lysomal ClC-7. Principal Findings.
Using a polyclonal affinity-purified antibody directed against a unique epitope in the ClC-6 COOH-terminal tail, we show that
human ClC-6, when transfected in COS-1 cells, is N-glycosylated in a region that is evolutionary poorly conserved between
mammalian CLC proteins and that is located between the predicted helices K and M. Three asparagine residues (N410, N422
and N432) have been defined by mutagenesis as acceptor sites for N-glycosylation, but only two of the three sites seem to be
simultaneously N-glycosylated. In a differentiated human neuroblastoma cell line (SH-SY5Y), endogenous ClC-6 colocalizes
with LAMP-1, a late endosomal/lysosomal marker, but not with early/recycling endosomal markers such as EEA-1 and
transferrin receptor. In contrast, when transiently expressed in COS-1 or HeLa cells, human ClC-6 mainly overlaps with markers
for early/recycling endosomes (transferrin receptor, EEA-1, Rab5, Rab4) and not with late endosomal/lysosomal markers (LAMP-
1, Rab7). Analogously, overexpression of human ClC-6 in SH-SY5Y cells also leads to an early/recycling endosomal localization
of the exogenously expressed ClC-6 protein. Finally, in transiently transfected COS-1 cells, ClC-6 copurifies with detergent-
resistant membrane fractions, suggesting its partitioning in lipid rafts. Mutating a juxtamembrane string of basic amino acids
(amino acids 71–75: KKGRR) disturbs the association with detergent-resistant membrane fractions and also affects the
segregation of ClC-6 and ClC-7 when cotransfected in COS-1 cells. Conclusions. We conclude that human ClC-6 is an
endosomal glycoprotein that partitions in detergent resistant lipid domains. The differential sorting of endogenous (late
endosomal) versus overexpressed (early and recycling endosomal) ClC-6 is reminiscent of that of other late endosomal/
lysosomal membrane proteins (e.g. LIMP II), and is consistent with a rate-limiting sorting step for ClC-6 between early
endosomes and its final destination in late endosomes.
Citation: Ignoul S, Simaels J, Hermans D, Annaert W, Eggermont J (2007) Human ClC-6 Is a Late Endosomal Glycoprotein that Associates with
Detergent-Resistant Lipid Domains. PLoS ONE 2(5): e474. doi:10.1371/journal.pone.0000474
INTRODUCTION
CLC proteins form an evolutionary conserved family of chloride
channels and/or transporters that are expressed from bacteria to
man [1]. The human genome contains 9 genes (CLCN1–7,
CLCNKA, CLCNKB) that encode the pore-forming a-subunits
(ClC-1 to -7, ClC-Ka and –Kb). In addition, auxiliary b-subunits
that affect plasma membrane location or expression level of the
a-subunit, have been described for ClC-Ka and –Kb (barttin) and
ClC-7 (Ostm1) [2,3]. More recently it has transpired that a-
subunits can differ in terms of subcellular location (plasma
membrane versus intracellular organelles) and mode of Cl
2
transport (Cl
2 channel versus Cl
2/H
+ antiporter) [4–7]. Conse-
quently, the mammalian a-subunits can be classified in two
subgroups, one functioning as plasma membrane Cl
2 channels
(ClC-1, -2, -Ka and –Kb) and another as intracellular Cl
2/H
+
antiporters (ClC-3 to -7). In mammals antiporter function has only
been formally shown for ClC-4 and ClC-5 [5,6], but the presence
of a conserved glutamate corresponding to E203 in the E. coli
ClC-ec1 that is responsible for H
+-coupling of Cl
2 transport [7],
suggests a similar antiporter mode for ClC-3, ClC-6 and ClC-7.
Some of the intracellular CLC’s have been located in specific
subcellular organelles: ClC-7 resides in late endosomes, lysosomes
and the osteoclast resorption lacuna [8], ClC-5 in endosomes in
the proximal tubule of the kidney [9,10] and ClC-3 in (late)
endosomes and synaptic vesicles [11]. Intracellular CLC’s are
thought to facilitate acidification of endosomal and lysosomal
compartments by dissipating the lumen-positive membrane
potential that arises from the electrogenic H
+-transport by the
V-type H
+-ATPase [12]. Nevertheless, alternative functions have
been proposed for intracellular CLC’s, such as fusion of
intracellular organelles [5] or trafficking of the endocytic receptor
proteins megalin and cubulin [13].
In spite of being cloned more than 10 years ago [14] ClC-6
remains an enigmatic member of the mammalian CLC family.
Sequence comparison shows ClC-6 to be most closely related to
the late endosomal/lysosomal ClC-7 [14], but little is known about
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oocytes or in COS cells failed to generate specific membrane
currents [14–16]. It should be added that in some instances
membrane currents were recorded in ClC-6 expressing Xenopus
oocytes, but identical currents were also observed in oocytes
expressing the non-related pICln protein and occasionally in
control oocytes indicating that ClC-6 expression affected the
expression of an endogenous anion channel [16,17]. Very recently,
it has been shown in a mouse model that loss of ClC-6 function
leads to a lysosomal storage disease resembling neuronal ceroid
lipofuscinosis [18].
In the present study we developed a specific antibody against
humanClC-6,whichrecognizestheproteinbothinWesternblotting
and in immunofluorescence studies. This made it possible to
determine the precise subcellular location of hClC-6 both endog-
enouslyinhuman neuronal SH-SY5Y cells andupon overexpression
in COS-1 and Helacells and to study its N-glycosylation pattern and
its association with detergent resistant membranes.
MATERIALS AND METHODS
Preparation of antiserum against human ClC-6
Rabbit antisera directed against human ClC-6 were raised against
the synthetic peptide RKRSQSMKSYPSSEL (corresponding to
residues 672–686 in hClC-6a) by Eurogentec (Seraing, Belgium).
The peptide was COOH-terminally conjugated to hemocyamin
and two rabbits were injected with the immunogen which
consisted of an emulsion of the conjugate solution and Freund’s
adjuvant. Booster injections of the same immunogen with
incomplete Freund’s adjuvant were given 4 times at 4-week
intervals. Both antisera were affinity-purified by the manufacturer.
Preparation of the expression vectors
Human ClC-6a (hClC-6) cDNA was obtained as described [16].
The cDNA was cloned into the pCINeo/IRES-GFP [19] and the
pcDNA3.1(2) (Invitrogen, Paisley, UK) expression vectors.
Mutants were made by overlap PCR [20] and involves the
amplification of two overlapping mutant fragments (PCR 1 and 2),
followed by amplification of the overlap fragment (PCR 3). Reaction
conditions were as follows for PCR 1 and 2: initial denaturation at
94uCfor5 min,30cyclesofdenaturationat94uCfor30 s,annealing
at 60uC for 1 min, extension at 72uC for 10 min with a final
extension at 72uC for 20 min. For PCR 3 the PCR parameters were
similar to those of PCR 1 and 2, except the annealing temperature
was augmented gradually between 50uCa n d6 8 uC during the 30
cycles. The PCR products were visualized by ethidium bromide
staining of a 1% agarose gel. The overlap fragment was eluted from
the gel with the GenElute
TM Gel Extraction Kit (Sigma-Aldrich, St.
Louis, MO, USA) and ligated into the pcDNA3.1(2) expression
vector using BamHI and HindIII restriction sites. Mutations were
verified using dye terminator-based sequencing (DYEnamic ET
Terminator Cycle Sequencing Kit, Amersham Biosciences, Piscat-
away, NJ, USA) on an automated MegaBACE sequencer (Amer-
sham Biosciences, Piscataway, NJ, USA).
Human ClC-7 was expressed with a pQBI/GFP-hClC-7 vector.
Expression vectors of COOH-terminally GFP fusions of Rab4,
Rab5, Rab7 and Rab11 proteins are pEGFP-C3 vectors as
described [21].
Cell culture and transfection
The human neuroblastoma SH-SY5Y cell line was obtained from
American Tissue Type Culture Collection CRL 1650 (Besthesda,
MD, USA). Cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 15% (v/v) fetal calf serum (FCS), 1%
glutamax; 1% (v/v) non-essential amino acids, 100 units/ml
penicillin and 100 mg/ml streptomycin. Cells were incubated in
a humified incubator at 5% CO2 and 37uC. From day 1 after
seeding, cells were differentiated in the presence of 10 mM all-trans-
retinoic acid (RA, Sigma-Aldrich) in cell medium containing 1%
FCS in the absence of light. After 6 days, the medium was
replaced by cell medium without FCS, containing 2 nM brain-
derived neurotrophic factor (BDNF, Sigma-Aldrich). After
48 hours differentiated cells were used for further experiments.
Transfections of differentiated SH-SY5Y were performed after
6 days of differentiation with retinoic acid (RA) using Lipofecta-
mine
TM 2000 transfection reagent (Invitrogen) as described in the
manufacturer’s protocol. After 24 hours, the medium was replaced
by cell medium without FCS, containing 2 nM BDNF and cells
were used for further experiments after 48 hours.
COS-1 SV 40 African monkey kidney cells, and HeLa epithelial
cells from an epidermoid carcinoma of the human cervix, were
cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% (v/v) fetal calf serum, 3.8 mM L-glutamine, 0.9% (v/v)
non-essential amino acids, 85 units/ml penicillin and 85 mg/ml
streptomycin. COS-1 cells were incubated in a humified incubator
at 9% CO2 and 37uC. HeLa cells were incubated in a humified
incubator at 5% CO2 and 37uC.
COS-1 and HeLa cells were transiently transfected with
expression vectors using Gene-JuiceH transfection reagent (Nova-
gen, Darmstadt, Germany) as described in the manufacturer’s
protocol. Transfections were performed the day after seeding.
Membrane preparation
Microsomes from transfected COS-1 cells were prepared as
described by Verbomen et al. [22].
Protein concentrations were determined by the bicinchonic acid
method (Pierce, Rockford, IL, USA).
Immunocytochemistry
SH-SY5Y cells, COS-1 and HeLa cells were grown on gelatine
coated coverslips. SH-SY5Y cells were differentiated as described
(see supra) and COS-1 and HeLa cells were transiently transfected
with different constructs. Cells were fixed in 3.7% paraformalde-
hyde for 15 min at room temperature and permeabilized with
0.2% Triton X-100 for 2 min at room temperature. Non-specific
binding was blocked by incubation for 5 h in PBS containing 3%
BSA. Primary antibodies were diluted in 3% BSA in PBS and
incubated overnight at 4uC. Immunofluorescence was performed
using the following primary antibodies: rabbit anti-hClC-6 (1:1000;
Eurogentec), mouse anti-EEA-1 (Clone 14, 1:150; BD Biosciences,
Erembodegem, Belgium), mouse anti-transferrin receptor (Clone
H68.4, 1:100; Invitrogen), mouse anti-LAMP-1 (H5G11, 1:100;
SantaCruz,California,USA),mouseanti-humanGolgin-97(CDF4,
1:200, Molecular Probes, Leiden, The Netherlands), mouse anti-
KDEL (recognizes BIP, Clone 10C3, 1:100; Stressgen Bioreagents,
AMUden,TheNetherlands).EEA-1,transferrinreceptor,LAMP-1,
Golgin-97, and BIP proteins function as markers for early
endosomes, recycling endosomes, late endosomes/lysosomes, Golgi
and ER, respectively. Secondary antibodies were added in 3% BSA
in PBS and incubated for 1 h at room temperature. Secondary
antibodies were goat anti-rabbit Alexa Fluor 488 or 594, or goat
anti-mouse Alexa Fluor 594 (Molecular Probes). Finally, the
coverslips were mounted in Vectashield (Vector Laboratories,
Brussels, Belgium) to inhibit photobleaching and nuclei were
visualized byaddingTO-PROH-3iodide (1:1000;MolecularProbes)
to the mounting medium. Samples were viewed by confocal laser
scanning microscopy (CLSM) using a Zeiss Radiance 2100 (Zeiss,
ClC-6: Endosome/Lipid Sorting
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microscope (objective 606, planAPO). Immunofluorescence data
were acquired using Lasersharp2000 (Zeiss) and finally processed by
Adobe Photoshop.
Preparation of detergent resistant membrane
fractions (DRM)
DRM fractions were prepared from transfected COS-1 cells as
described [23]. Cells were washed twice with PBS and lysed for
1 h on ice in excess (10-fold excess (w/w) over protein), ice-cold
Triton X-100 (1%) buffer containing 25 mM Tris (pH 7.4),
100 mM NaCl, 90 mM Mannitol, 1 mM EGTA, 2 mM DDT
and protease inhibitor cocktail (Sigma Aldrich). The lysate was
separated by upward flotation on a sucrose gradient as described
earlier. Upward flotation of DRM’s was verified by Western
blotting and immunostaining with a monoclonal anti-caveolin-1
antibody (1/1000; BD Biosciences) and a polyclonal anti-Fyn
antibody (FYN3, 500 ng/ml; Santa Cruz; data not shown). All
blots were tested by immunostaining with a monoclonal anti-
transferrin receptor antibody (1 mg/ml; Invitrogen) as a negative
control. Fractions were tested for distribution of hClC-6 (wild type
and AAGAA-mutant) by Western blotting and immunostaining
with the polyclonal a-hClC-6 antibody (1:1000). DRM fractions
were also prepared from GFP-hClC-7 overexpressing COS-1 cells
and immunostained for caveolin-1, transferrin receptor and GFP
(GFP Monoclonal Antibody, 1:500; Clontech).
Deglycosylation studies
Digestions with Peptide N-glycosidase F (PNGaseF, New England
Biolabs, Ipswick, MA, USA) which removes both core (mannose-
rich) and complex (trimmed and modified) glycans or with
Endoglycosidase H (EndoH, New England Biolabs) which removes
core but not complex glycans, were performed as advised by the
supplier on 20 mg of glycoprotein with a preliminary denaturation
step during 24 hours on 37uC. Tunicamycin (Sigma-Aldrich) which
blocks the first step in the N-glycosylation process (transfer of the
mannose-rich core glycan from the dolichol carrier to an asparagine
acceptor),wasadded4 hoursaftertransienttransfectionoftheCOS-
1cellswithhClC-6aWTormutantsinafinalconcentrationofeither
0.05 or 0.1 mg/ml during a 36-h period.
SDS PAGE and Western-Blot analysis
Microsomes from COS-1 cells, transiently transfected with the
different constructs, were analysed by NuPAGE
TM 4–12% (v/v)
Bis-Tris SDS-PAGE gels using MOPS-buffer (Invitrogen), follow-
ing the manufacturer’s protocol. After electrophoresis, the
separated proteins were transferred onto a PVDF membrane
(Immobilon-P; Millipore, Bedford, MA, USA) by semi-dry
electroblotting. The blots were blocked overnight at 4uC in PBS
containing 0.1% (v/v) Tween-20 and 5% (w/v) non-fat dry milk
powder. The blots were incubated with the primary antibody and
subsequently with the horseradish peroxidase (HRP) conjugated
secondary antibody. The immunoreactive bands were visualized
with SuperSignalH West Pico Chemiluminescent Substrate (Pierce)
and exposed to HyperFilm. The HyperFilm was developed using
a KODAK X-Omat 1000 (KODAK, Rochester, NY, USA).
RESULTS
The polyclonal a-hClC-6 antibody recognizes human
ClC-6 (hClC-6) in transiently transfected cells
A short peptide (amino acids 672–686) in the COOH-terminal
cytosolic tail of hClC-6 was selected to raise affinity-purified
polyclonal antibodies against hClC-6 (Fig. 1). The antibodies were
first tested on Western blots using microsomal membrane fractions
of COS-1 cells, either wild type or transiently transfected with
a hClC-6 expression vector (Fig. 2A). Incubation with the
polyclonal a-hClC-6 antibody resulted in a strong band of
approximately 100 kDa (theoretical molecular mass of unglycosy-
lated hClC-6 is 96 kDa, but see further) in hClC-6 expressing
COS-1 cells, but not in untransfected wild type COS-1 cells
(Fig. 2A). A similar result was obtained in transfected HeLa cells
(data not shown). The specificity of the a-hClC-6 antibody was
confirmed by incubating Western blots with pre-immune serum or
a-hClC-6 antibody pre-adsorbed to the epitope peptide. The pre-
immune serum failed to visualize the 100 kDa band in hClC-6
expressing COS-1 cells, whereas pre-adsorption caused a nearly
complete disappearance of the 100 kDa band (Fig. 2A). Sub-
sequently the a-hClC-6 antibody was tested for immunofluores-
cence experiments (Fig. 2B). Therefore, COS-1 cells transiently
transfected with a bicistronic GFP/hClC-6 expression vector [19]
were incubated with pre-immune serum (Fig. 2Ba–b) or the a-
hClC-6 antibody (Fig. 2Bc–d). Specific staining was only observed
Figure 1. Development of a polyclonal antibody against human ClC-6
(hClC-6). Multiple sequence alignment (ClustalW) of all human CLC
proteins revealed a COOH-terminal region that is unique for ClC-6 (aa
639–740). This region interrupts the first cystathionine-b synthase (CBS)
domain in the COOH-terminal cytosolic tail [52]. Polyclonal antibodies
were raised against an epitope (aa 672–686; red box) in this unique
region.
doi:10.1371/journal.pone.0000474.g001
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GFP-expressing cells.
Next we tested whether the a-hClC-6 antibody cross-reacted with
hClC-7 as ClC-6 is most closely related to ClC-7 [14]. To do so,
COS-1 cells were transiently transfected with a GFP-hClC-7
expression vector that encodes human ClC-7 with a GFP fused at
the NH2-terminus. Although ClC-7 expression levels were high, as
shown by the Western blot using anti-GFP antibody, no cross-
reactivity was found for the a-hClC-6 antibody (Fig. 2C). We
therefore conclude that the polyclonal a-hClC-6 antibody specifi-
cally recognizes hClC-6 when transiently expressed in COS-1 cells,
bothonWesternblotandindirectimmunofluorescenceexperiments.
hClC-6 is N-glycosylated on multiple positions.
Incubation of transfected COS-1 cells with tunicamycin (0.1 mg/
ml) significantly increased the mobility of hClC-6 (65 kDa as
compared to 100 kDa) demonstrating that it is N-glycosylated
(Fig. 3A). At a lower concentration (0.05 mg/ml) tunicamycin
induced the appearance of several intermediate bands between
100 and 65 kDa indicating multiple glycosylation of hClC-6 (see
below). A similar reduction in molecular mass was observed when
hClC-6 was treated with PNGaseF (Fig. 3Aa). In contrast, EndoH
did not affect the electrophoretic mobility of hClC-6 (Fig. 3Ab).
The tunicamycin- and PNGaseF-sensitivity in combination with
the EndoH resistance indicates that hClC-6 carries complex N-
glycans that have been processed and modified in the Golgi
apparatus. Furthermore, there is a discrepancy between the
apparent molecular mass on SDS-PAGE (100 kDa for glycosy-
lated hClC-6 and 65 kDa for non-glycosylated hClC-6) and the
predicted molecular mass (97 kDa for the non-glycosylated
protein). Proteolytic cleavage of hClC-6 was excluded since the
same band was detected by the a-hClC-6 antibody which
recognizes an epitope in the COOH-terminal tail, and an anti-
Myc antibody directed at a Myc epitope tag inserted at the hClC-6
NH2-terminus (data not shown). The faster migration pattern on
SDS-PAGE most likely reflects anomalous migration as has also
been reported for ClC-5 [24].
We then proceeded to identify the N-glycosylated asparagine
residues in hClC-6. Sequence analysis of hClC-6 revealed 7
potential N-glycosylation motifs (N-X-[S,T] with X any amino
acid except proline). Modeling of hClC-6 on the crystal structure
of prokaryote ClC indicated that four asparagines, i.e. N137,
N410, N422 and N432, were located in an exoplasmic loop or at
the exoplasmic end of a membrane helix and are therefore
positioned at the correct topological position for N-glycosylation:
N137 is located at the exoplasmic end of helix C and N410, N422,
N432 are located in an exoplasmic region between helices K and
M (Fig. 3B). To find out which asparagines are N-glycosylated
these residues were mutated to alanine, either individually or in
group. The quadruple mutant (AAAA-hClC-6: N137A/N410A/
N422A/N432A) and the triple mutant (AAA-hClC-6: N410A/
N422A/N432A) migrated on SDS-PAGE with the same mobility
as non-glycosylated hClC-6 (tunicamycin treatment; Fig. 3Ca).
Since there was no difference between AAA-hClC-6 and AAAA-
hClC-6, it appears that N137 is not glycosylated and that N-
glycosylation is limited to the asparagine residues in the region
between helices K and M. This was tested by introducing single
and double mutations for N410, N422 and N432. All double
mutants (NAA-hClC-6: N422A/N432A; ANA-hClC-6: N410A/
N432A; AAN-hClC-6: N410A/N422A) were glycosylated as
indicated by their higher apparent molecular mass than non-
glycosylated hClC-6 and by their PNGaseF sensitivity (Fig. 3Cb
and 3Cd). Importantly, wild type hClC-6 migrated slower than the
double mutants which is consistent with hClC-6 carrying more
Figure 2. Characterization of the polyclonal a-hClC-6 antibody. (A)
Western blotting of microsomal membranes of wild-type COS-1 cells and
COS-1 cells transiently transfected with pcDNA3.1(2)/hClC-6a. Incubation
with the affinity-purified polyclonal a-hClC-6 resulted in a band of
approximately 100 kDa in transfected COS-1 cells, but not in wild type
COS-1 cells. Such a band was not observed in transfected COS-1 cells
when the blot was incubated with pre-immune serum or when the
polyclonal a-hClC-6 was preincubated with the epitope-peptide before
applying to the blot. (B) Immunofluorescence of COS-1 cells transfected
with the bicistronic vector pcINeo/GFP-IRES/hClC-6a which ensures strict
coupling between GFP expression (green signal in panels a and c) and
ClC-6 expression. Incubation with pre-immune serum (panel b) never
generated a positive signal in transfected cells. In contrast, a positive
signal for ClC-6 (red in panel d) was exclusively observed in transfected
cells incubated with polyclonal a-hClC-6. Nuclei were counterstained with
blue TO-PROH-3. The scale bar corresponds to 10 mm. (C) Western blot of
microsomal membrane fractions from transiently transfected COS-1 cells
expressing either hClC-6 or GFP-hClC-7. Incubation with a-hClC-6
generated a positive signal in the hClC-6 expressing membrane fractions,
but not in the hClC-7 expressing membranes. Expression of GFP-hClC-7
was confirmed by incubation with a monoclonal a-GFP antibody.
doi:10.1371/journal.pone.0000474.g002
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single mutants (NNA-hClC-6: N432A; NAN-hClC-6: N422A;
ANN-hClC-6: N410A, Fig. 3Cc and 3Cd) which contain two
potential N-glycosylation sites. These were all PNGaseF-sensitive
and migrated slower than the (monoglycosylated) double mutants
which is compatible with the addition of a second glycan.
However, wild type hClC-6 and the single mutants migrated at
the same position indicating that in wild type hClC-6 only 2 of the
3 potential glycosylation sites are effectively used.
Endogenous hClC-6 colocalizes with LAMP-1 in
a human neuronal SH-SY5Y cell line
A crucial question with respect to the intracellular CLC’s deals
with their specific subcellular location. We therefore examined by
means of confocal laser scanning microscopy (CLSM) the
subcellular distribution of endogenous human ClC-6 in a differen-
tiated neuronal cell line SH-SY5Y cells (Fig. 4). ClC-6 displays
a punctuated pattern that is present both around the nucleus in the
cell body and in the neuronal outgrowths. There is no substantial
overlap with the early endosomal marker EEA-1 (Fig. 4A) nor with
transferrin receptor (TfR; Fig. 4B), a marker for recycling
endosomes [25]. However, endogenous ClC-6 strongly colocalized
with LAMP-1 (a marker for late endosomes/lysosomes) both
perinuclearly and in the cell periphery (Fig. 4C). This is in
agreement with Poe ¨t et al. [18] who have recently reported that in
mouse brain sections ClC-6 mainly colocalizes with LAMP-1 and
concluded that ClC-6 resides in a late endosomal compartment.
Immunolocalization of hClC-6 in transiently
transfected COS-1 and HeLa cells
Complementary experiments with respect to the subcellular
localization of hClC-6 were performed in transiently transfected
Figure 3. hClC-6 is glycosylated upon overexpression. (A) Western blots showing the effect of tunicamycin and (a) PNGaseF and (b) EndoH on hClC-
6. For tunicamycin COS-1 cells were incubated with tunicamycin (0.05 and 0.1 mg/ml) for 36 hours; for PNGaseF and EndoH membrane fractions of
hClC-6 expressing COS-1 cells were treated as described in materials and methods. ‘WT’ refers to untreated hClC-6. The small difference in molecular
mass between PNGaseF and tunicamycin-treated hClC-6 might be due to the presence of oligosaccharides carrying fucose-linked a1–3 to the GlcNac
attached directly to asparagines, which are PNGaseF resistant as described by Dwek et al. [53]. (B)(a), Model of the hClC multimeric structure of 2
homologous subunits with the possible glycosylation sites marked as spheres. (b), Partial sequence alignment (ClustalW) of all members of the CLC
family reveals that Asn residues that possibly participate in glycosylation (marked in red) in hClC-6 are situated in a region that is poorly conserved
among the other members of the CLC family and located between predicted helices K and M. (C) Western blots of membrane fractions of COS-1 cells
expressing WT or mutant hClC-6. (a), Glycosylation pattern of the triple (AAA: N410A/N422A/N432A) and quadruple (AAAA: N137A/N410A/N422A/
N432A) mutant compared to WT and WT with tunicamycin. (b), Glycosylation pattern of the double mutants (AAN: N410A/N422A; ANA: N10A/N432A;
NAA: N422A/N432A) compared to glycosylated WT and the triple mutant (AAA). (c), Glycosylation pattern of the single mutants (ANN: N410A, NAN:
N422A, NNA: N432A) compared to the glycosylated WT and deglycosylated WT treated with tunicamycin. (d), Effect of PNGaseF treatment on a single
(ANN: N410A) and double (AAN: N410A/N422A) mutant compared to WT and triple (AAA) mutant. (e), Effect of EndoH treatment on a single (ANN:
N410A) and double (AAN: N410A/N422A) mutant compared to WT and triple (AAA) mutant. Bands marked with an asterisk, occasionally observed in
the WT protein and frequently observed in single mutants after sustained exposure represent possible intermediary biosynthetic products, which are
PNGaseF-sensitive and EndoH-insensitive as shown in panels (d) and (e).
doi:10.1371/journal.pone.0000474.g003
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staining pattern often residing in relatively large (a few micrometer
in diameter) vesicular structures (Fig. 5). The distribution pattern
of hClC-6 clearly did not overlap with endoplasmic reticulum
(BIP, Fig. 5A) nor with the Golgi markers Golgin-97 (Fig. 5B) or
GM130 (not shown). A partial overlap with Golgin-97 was
observed in a few transfected cells. In contrast to endogenous ClC-
6 in SH-SY5Y cells, transiently expressed hClC-6 did not overlap
with LAMP-1 in COS-1 cells (Fig. 5C), but it showed substantial
colocalization with markers for early endosomes (EEA-1) or the
recycling pathway (TfR).
The endosomal localization was further dissected via co-
expression of hClC-6 with Rab4, Rab5, Rab7 and Rab11 which
are established marker proteins for early endosomes (Rab5)
[26,27], late endosomes/lysosomes (Rab7) [28] and recycling
endosomes (Rab4 and Rab11) [29–32]. Because of the better
morphology, these experiments were conducted in HeLa cells co-
expressing hClC-6 and a GFP-Rab fusion protein using CLSM
(Fig. 6), but similar data were acquired in COS-1 cells (data not
shown). From panels C and D in Fig. 6 it is clear that little or no
overlap was found with Rab7 (Fig. 6C) nor with Rab11 (Fig. 6D).
For Rab7 this was not surprising given the lack of colocalization
with LAMP-1 (see above). However, there was partial colocaliza-
tion with Rab5 (Fig. 6B) and an even better overlap with Rab4
(Fig. 6A). Thus, during transient overexpression in COS or HeLa
cells hClC-6 ends up in an endosomal compartment that is positive
for early endosomal markers (EEA-1 and Rab5) and a subset of
recycling endosomal markers (TfR and Rab4; see Discussion for
a further description of this compartment). In this respect it should
be pointed out that not only Rab11-positive, but also Rab4-
positive endosomes are found in the perinuclear region [21] which
would account for the perinuclear signal of overexpressed hClC-6.
We also investigated whether N-glycosylation is required for
endosomal location of hClC-6 in transfected HeLa cells. CLSM of
the glycosylation-deficient AAAA-hClC-6 (data not shown) and
AAA-hClC-6 showed substantial colocalization with Rab4 (Fig. 6E)
indicating that glycosylation is not essentially required for delivery
to the endosomal compartment. A similar overlapping pattern
with Rab4 was observed for the single and double N-glycosylation
mutants (data not shown).
Immunolocalization of overexpressed hClC-6 in the
neuronal SH-SY5Y cell line
Since the expression pattern of overexpressed hClC-6 in COS-1
and HeLa cells differed from the endogenous hClC-6 distribution
Figure 4. Immunolocalization of endogenous hClC-6 in SH-SY5Y cells. Double immunofluorescence confocal images of SH-SY5Y cells. hClC-6 (left
column) was detected using the polyclonal a-hClC-6 antibody and visualized with anti-rabbit IgG antibodies conjugated to Alexa Fluor 488 (green
signal). Markers for different endosomal compartments (middle column) were (A) mouse anti-EEA-1 (an early endosome marker); (B) mouse anti-
transferrin receptor (TfR, an early/recycling endosome marker); (C) mouse anti-LAMP-1 (a late endosomal/lysosomal marker). The marker antibodies
were visualized by anti-mouse IgG antibodies conjugated to Alexa Fluor 594 (red signal). In the merged pictures (right column) colocalization is
indicated by a yellow signal. The scale bars represent 10 mm.
doi:10.1371/journal.pone.0000474.g004
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PLoS ONE | www.plosone.org 6 May 2007 | Issue 5 | e474Figure 5. Immunolocalization of hClC-6 in transfected COS-1 cells. Double immunofluorescence confocal images of COS-1 cells transiently
transfected with pcDNA3.1(2)/hClC-6a. hClC-6 expression (left column) was detected using the polyclonal a-hClC-6 antibody and visualized with anti-
rabbit IgG antibodies conjugated to Alexa Fluor 488 (green signal). Organelles were stained with the following antibodies or markers (middle
column): (A) mouse anti-BIP (an endoplasmic reticulum marker); (B) mouse anti-Golgin-97 (a Golgi marker); (C) mouse anti-LAMP-1 (a late endosomal/
lysosomal marker); (D) mouse anti-EEA-1 (an early endosome marker); (E) mouse anti-transferrin receptor (TfR, an early/recycling endosome marker).
The marker antibodies were visualized by anti-mouse IgG antibodies conjugated to Alexa Fluor 594 (red signal). The column on the right shows
merged pictures of ClC-6 expression and marker staining with yellow indicating colocalization. The scale bars represent 10 mm.
doi:10.1371/journal.pone.0000474.g005
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PLoS ONE | www.plosone.org 7 May 2007 | Issue 5 | e474Figure 6. Colocalization of overexpressed hClC-6 with different endosomal Rab-proteins. Confocal images of double transiently transfected HeLa
cells, expressing hClC-6 and (A) GFP-Rab4, (B) GFP-Rab5, (C) GFP-Rab7, (D) GFP-Rab11. hClC-6 was detected with the polyclonal a-hClC-6 antibody
and visualized with anti-rabbit IgG antibodies conjugated to Alexa Fluor 594. The Rab signals were visualized by the GFP signal. (E) Represents
a confocal image of double transiently transfected COS-1 cells, expressing the glycosylation-deficient AAA-hClC-6 (red signal) and GFP-Rab4 (green
signal). The scale bars represent 10 mm.
doi:10.1371/journal.pone.0000474.g006
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discrepancy reflects cell type-specific differences in protein sorting
in the endosomal system or, alternatively, whether this is the result
of overexpression.
Therefore, we transiently transfected differentiated SH-SY5Y
cells with an hClC-6 expression vector and determined the
distribution of overexpressed hClC-6 by means of CLSM. The
overexpression levels in transfected cells were very high, so that
transfected cells could easily be distinguished from non-transfected
cells. As in COS-1 and HeLa cells, the overexpressed hClC-6
displayed a perinuclear staining pattern (Fig. 7). This pattern
partially overlapped with the early endosomal marker EEA-1
(Fig. 7A) and recycling endosomal pathway marker TfR (Fig. 7B),
but not with the late endosomal marker LAMP-1 (Fig. 7C).
Furthermore, after cotransfection of hClC-6 with a Rab4-GFP
expression vector we observed a high degree of colocalization,
analogous to overexpression in COS-1 and HeLa cells (data not
shown). Thus, although SH-SY5Y cells can sort endogenous ClC-
6 to a LAMP-1 positive compartment, hClC-6 does not reach this
compartment upon overexpression.
hClC-6 resides in detergent resistant membrane
fractions in transiently transfected COS-1 cells
In a final series of experiments we investigated whether hClC-6
associates with detergent resistant membrane (DRM) fractions.
Transiently transfected COS-1 cells were lysed with Triton X-100
at 4uC and DRM’s were separated by flotation on a sucrose
gradient. Western blot analysis of the gradient fractions (equal
amount of volume) showed that overexpressed hClC-6 co-
distributed with caveolin-1 in the upper part of the sucrose
gradient corresponding to the DRM fractions (Fig. 8A). In
contrast, the transferrin receptor which does not associate with
detergent resistant membranes [33], did not float upwards in the
sucrose gradient (Fig. 8A). It has been shown that DRM
association of CD4, an intrinsic membrane protein, critically
depends on a cytosolic, membrane-proximal stretch of positively
charged amino acids (RHRRR) [34]. Intriguingly, hClC-6
contains a similar positively charged sequence KKGRR (amino
acids 71–75) immediately upstream and at the cytosolic side of the
first transmembrane helix B. Indeed, mutation of KKGRR into
AAGAA disrupted the DRM association (Fig. 8Ab). The large
Figure 7. Immunolocalization of overexpressed hClC-6 in SH-SY5Y cells. Double immunofluorescence confocal images of SH-SY5Y cells, transiently
transfected with pcDNA3.1(2)/hClC-6a expression vector. Overexpression levels were very high, so that transfected cells could easily be distinguished
from non-transfected cells. Overexpressed hClC-6 (left column) was detected using the polyclonal a-hClC-6 antibody and visualized with anti-rabbit
IgG antibodies conjugated to Alexa Fluor 488 (green signal). Markers for different endosomal compartments (middle column) were (A) mouse anti-
EEA-1 (an early endosome marker); (B) mouse anti-transferrin receptor (TfR, an early/recycling endosome marker); (C) mouse anti-LAMP-1 (a late
endosomal/lysosomal marker). Primary antibodies were visualized using anti-mouse IgG antibodies conjugated to Alexa Fluor 594 (red signal). In the
merged pictures (right column) colocalization is indicated by a yellow signal. The scale bars represent 10 mm.
doi:10.1371/journal.pone.0000474.g007
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PLoS ONE | www.plosone.org 9 May 2007 | Issue 5 | e474majority of AAGAA-hClC-6 failed to float upwards and remained
at the bottom of the sucrose gradient together with the transferrin
receptor.
Strikingly, the KKGRR/AAGAA mutation also affected the
segregation of ClC-6 and ClC-7. Although Suzuki et al. reported
a significant colocalization between ClC-6 and ClC-7 cotrans-
fected in HEK293 cells [35], we observed a clear separation of
both CLC proteins when cotransfected in COS-1 cells. Indeed,
wild-type hClC-6 and ClC-7 resided either in different vesicles or
in different microdomains of the same vesicle upon cotransfection
(Fig 8Ba–c). However, the distribution of AAGAA-hClC-6 and
ClC-7 overlapped substantially as shown by the yellow pattern in
the merged panel (Fig. 8Bd–f) suggesting (partial) colocalization of
AAGAA-ClC-6 and ClC-7. DRM analysis showed that ClC-7
floated upwards in a sucrose gradient, but contrary to ClC-6 it did
not reach the caveolin-1-positive fractions at the top of the sucrose
gradient (data not shown). Finally, N-glycosylation was not
important for DRM association of hClC-6, since the triple mutant
hClC-6 (AAA-hClC-6: N410A/N422A/N432A) still floated
upwards in the sucrose gradient (data not shown).
DISCUSSION
We have developed a polyclonal antibody against human ClC-6
which has enabled us to study the N-glycosylation profile and the
subcellular distribution of hClC-6 both endogenously in the
neuronal SH-SY5Y cell line and in transiently transfected COS-1
or Hela cells. Our data are consistent with hClC-6 being a multiply
N-glycosylated membrane protein that is targeted to late
endosomes in neuronal cells. In transfected COS-1 cells hClC-6
resides in a lipid raft microenvironment and the association with
detergent resistant membrane fractions is critically dependent on
the positively charged juxtamembranous KKGRR sequence
(amino acids 71–75).
The glycosidase profile of hClC-6 (PNGaseF-sensitive, but
EndoH resistant) indicates that hClC-6 acquires fully processed,
mature N-glycans and therefore that hClC-6 traverses the Golgi
apparatus during its biosynthesis. This most likely explains the
occasional overlap of ClC-6 with Golgi markers such as Golgin-97
(our observation) or GM-130 [35]. Three asparagine residues
(N410, N422 and N432) were identified as N-glycosylation sites,
but only two of the three sites are effectively glycosylated in the
wild type protein. Whether this is due to steric hindrance, e.g. that
the short loop between N410 and N432 can sterically only
accommodate two glycan moieties, or to other limiting factors
such as the sequence context or associated proteins, is currently
not known. An aspartate at the X position in the glycosylation
sequon N-X-S/T and a serine at the +2 position reduce the
efficiency of N-glycosylation [36]. Thus, the specific sequence
context of the hClC-6 glycosylation sites (N410-D-S; N422-S-S;
N432-D-T) could contribute to their less efficient usage. The
amino acid sequence of the predicted exoplasmic region contain-
ing N410, N422 and N432 is poorly conserved between the
mammalian CLC’s. Furthermore, except for ClC-7, all mamma-
lian CLC’s contain one or more consensus sites for N-glycosylation
in this region (Fig. 3B). N-glycosylation has been experimentally
confirmed for human ClC-1 (N430) [37], rat ClC-K1/K2 (N364
and/or N373) [38] and Xenopus laevis ClC-5 (N470) [39].
Furthermore, it is very likely that one or more of the predicted
sites in human and mouse ClC-3 and human ClC-5 are effectively
occupied by a N-glycan, because of the PNGaseF sensitivity of
these proteins [40–43]. Thus, based on the glycosylation pattern in
the K-M region non-glycosylated (e.g. ClC-7), monoglycosylated
(e.g. ClC-1) and multiple glycosylated (e.g. ClC-6) isoforms can be
distinguished among mammalian CLC’s. Because of these
sequence and glycosylation variations the exoplasmic K-M region
emerges as a highly divergent stretch in mammalian CLC’s and is
therefore a prime candidate for isoform-specific interactions with
extracellular or luminal proteins affecting their function, bio-
synthesis, degradation and/or sorting. However, there are few
experimental data available with respect to the functional
significance of glycans in CLC proteins. For the plasma membrane
ClC-1, it has been reported that glycosylation-deficient channels
Figure 8. hClC-6 resides in detergent resistant membrane fractions. (A) DRM fractions of COS-1 cells overexpressing respectively (a) hClC-6 and (b)
KKGRR/AAGAA-hClC-6; were prepared and separated on a sucrose gradient. Upward flotation of the DRM’s was checked by distribution of caveolin-1
(Cav-1) which migrated to the top of the gradient (fractions 2/3/4). Transferrin receptor (TfR), a non-raft membrane protein, was used as a negative
control (fractions 8/9 at the bottom of the gradient). hClC-6 expression was checked by staining with the polyclonal a-hClC-6. (B) Confocal images of
double transiently transfected COS-1 cells, expressing GFP-hClC-7 and wild type hClC-6 (panels a to c) or KKGRR/AAGAA-hClC-6 (panels d to f). Wild
type and KKGRR/AAGAA-hClC-6 were detected with the polyclonal a-hClC-6 antibody and visualized with anti-rabbit IgG antibodies conjugated to
Alexa Fluor 594 (red signal, panels a and d). ClC-7 expression is visualized by the GFP signal (green signal, panels b and e). A yellow signal indicates
colocalization (panels c and f). Scale bars represent 10 mm.
doi:10.1371/journal.pone.0000474.g008
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characteristics [38]. N-glycosylation enhances plasma membrane
expression of Xenopus ClC-5, but it is not required for its
endosomal localization [39]. Similarly, non-glycosylated ClC-6
was still able to reach its endosomal location in COS-1 and HeLa
cells, but we cannot exclude a role of N-glycosylation in late
endosomal sorting. Moreover, the lack of a functional read out
system for ClC-6 precludes drawing definitive conclusions about
the functional importance of N-glycosylation in ClC-6.
At first sight there seems to be a contradiction between the late
endosomal location of endogenous ClC-6 in SH-SY5Y cells and
the colocalization with early/recycling endosomal markers when
ClC-6 is overexpressed in COS-1, HeLa and SH-SY5Y cells.
However, one can draw an interesting comparison with LIMP II,
a bona fide late endosomal/lysosomal membrane protein [44].
When overexpressed in COS cells, LIMP II induces the
appearance of large vesicular structures which are positive for
EEA-1 and transferrin receptor [45]. Furthermore, LIMP II
overexpression impairs membrane traffic out of the early
endosomal compartment. Kuronita et al. [45] therefore concluded
that LIMP II is sorted to late endosomes/lysosomes via the early
endosomal compartment and contributes to the biogenesis of late
endosomes/lysosomes by controlling a crucial step in vesicular
transport between early and late endosomes. The parallel
behaviour of ClC-6 (appearance of enlarged vesicles upon
overexpression; endogenous ClC-6 in late endosomes versus
overexpressed ClC-6 in early endosomes) prompts several
hypotheses with respect to the cell biology of ClC-6. First, it is
consistent with the routing of ClC-6 to late endosomes via an early
endosomal compartment. In transfected cells exit of ClC-6 from
this early compartment seems to be the rate-limiting step, whereas
endogenous ClC-6 leaves the early endosomal compartment and is
sorted to late endosomes. Second, the enlarged vesicles upon
overexpression in COS-1 cells may point to a role of ClC-6 in
vesicular transport out of the early compartment. If so, ClC-6
could contribute to late endosomal/lysosomal biogenesis which
would explain the lysosomal storage disease phenotype in ClC-6
knock-out mice [18].
It is tempting to interpret the sorting and function of ClC-6 in
the context of the Tubular Endosomal Network (TEN) model
which has recently been proposed by Bonifacino and Rojas [46].
In this model, the endosomal compartment is divided in a vacuolar
part and a tubular extension, the TEN. The vacuolar compart-
ment corresponds to the early endosomal compartment and is the
entry site for cargo-containing vesicles derived from the plasma
membrane or the trans-Golgi-network (TGN). Proteins that are
not destined for lysosomal degradation are separated from the
degradative cargo and transported from the early endosomal
compartment to the TEN where they are further sorted to specific
microdomains from which cargo-loaded vesicles bud off. The
microdomains in TEN form exit sites for recycling endosomes that
return to the plasmamembrane (e.g. TfR), for retrograde transport
vesicles going back to the TGN (e.g. Mannose-6-Phosphate
Receptor) and for the lysosomal bypass route via which vesicles
containing late endosomal/lysosomal membrane proteins such as
LAMP’s and LIMP’s are sorted to late endosomes [47]. Based on
this model, we propose that ClC-6, once it has reached the early
endosome, is sorted to the TEN which it leaves via the lysosomal
exit site to finally arrive in late endosomes. In transfected cells
(COS-1, HeLa, SH-SY5Y) ClC-6 seems to be correctly sorted to
TEN as can be deduced from its overlap with early and recycling
endosomal markers, but it apparently cannot enter the lysosomal
bypass route and therefore does not end up in late endosomes.
How would overexpression interfere with the proper sorting of
ClC-6? One possibility is that late endosomal delivery of ClC-6
requires an additional factor (a b-subunit as for ClC-Ka/Kb, an
adaptor/coat protein required for vesicular transport, …) that is
expressed in limiting quantities which are sufficient for correct
sorting of the endogenous ClC-6, but insufficient for abundantly
overexpressed ClC-6. Alternatively, ClC-6 could be mechanisti-
cally involved in the late endosomal sorting (see below) so that
overexpression of ClC-6 would block this sorting step.
Given that ClC-6 resides in the lysosomal bypass route, what
function would it fulfill? Initially, intracellular CLC’s were thought
off as Cl
2 channels facilitating acidification of the organellar
lumen by providing an electrogenic shunt for the lumen-positive
membrane potential generated by the V-type H
+-pump [12].
However, loss of ClC-6 or ClC-7 does not affect the lysosomal pH
in respectively ClC6 2/2 and ClC-7 2/2 mice [48] indicating
that ClC-6 and ClC-7 are not essential for lysosomal acidification.
Furthermore, intracellular CLC’s most likely function as Cl
2/H
+-
antiporters [5,6] and they can therefore acidify (and increase the
luminal Cl
2 concentration) or alkalinize (and decrease the luminal
Cl
2 concentration) endosomes depending on the electrical, pH
and Cl
2 gradient across the endosomal membrane. This raises the
possibility that intracellular CLC’s exert an effect on endosomal
traffic and/or endosome/lysosome biogenesis by changing the
endosomal pH and/or the luminal Cl
2 concentration. An
alternative, not necessarily mutually exclusive, mechanism is that
endosomal CLC’s function as pH or Cl
2 sensors that couple
changes in lumenal pH or Cl
2 to conformational changes in their
cytosolic domains which could trigger the recruitment of cytosolic
factors to the endosome membrane to control specific steps in
vesicular transport. Interestingly, such a pH-sensing function has
recently been shown for the V-type H
+-pump in early endosomes
[49]. Also, it has very recent been shown that gating of ClC-0 (i.e.
the binding of Cl
2 in the channel pore) causes a conformational
change of its carboxyterminus [50].
Finally, our data show that in transiently transfected COS-1
cells hClC-6 associates with detergent-resistant membrane do-
mains suggesting that ClC-6 segregates to lipid rafts. DRM
association may be a common theme for CLC proteins since ClC-
2 also concentrates in cholesterol-enriched lipid domains which
affects the gating properties of the channel [51]. Moreover, the
DRM association critically depends on a positively charged amino
acid sequence KKGRR which according to the CLC topology
model is located immediately N-terminal of helix B, the first
transmembrane segment. The positive charge and the cytosolic,
membrane-proximal location of this sequence are reminiscent of
the RHRRR sequence that functions as a raft localization marker
for the CD4 receptor. Surprisingly, mutating the KKGRR
sequence also affected the colocalization of ClC-6 with ClC-7.
In cotransfection experiments, wild-type ClC-6 and ClC-7 can be
spatially resolved on CSLM, whereas AAGAA-ClC-6 and ClC-7
colocalize to a large extent. Whether the differential sorting of wild
type ClC-6 and ClC-7 is a lipid-based mechanism (ClC-6 and
ClC-7 seem to associate with different lipid domains), or,
alternatively, whether protein interactions involving the KKGRR
sequence are the driving component, is not clear. Irrespective of
the mechanism our data identify the KKGRR sequence as an
important cis-acting element for the correct sorting and delivery of
ClC-6. However, additional experiments are needed to verify the
DRM association of endogenous ClC-6 and the specific effects
exerted by the KKGRR sequence on the endogenous sorting
process.
To conclude, we have shown that human ClC-6 is an N-
glycosylated protein and the N-glycosylation sites have been
identified. We have also found a positively charged motif in the N-
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segregation from ClC-7 in transfected COS-1 and HeLa cells.
Furthermore, our data suggest that upon overexpression in COS-1
and HeLa cells, ClC-6 does not reach the late endosomal
compartment, but is retained in an early endosomal compartment
that may correspond to the tubular endosomal network. We
propose that endogenous ClC-6 leaves the tubular endosomal
network via the lysosomal exit site to finally reach the late
endosomes. This model puts ClC-6 at the heart of the late
endosomal/lysosomal biogenesis route which could explain the
lysosomal storage disease phenotype in ClC-6 knock-out mice
[18].
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